Lansen Pharmaceutical Holdings Limited provided earnings guidance for the six months ended 30 June 2021. For the period, the Group's revenue is expected to record a moderate decrease as compared with that of the same period last year; the Group's operating profit is expected to record a significant decrease as compared with that of the same period last year; and the Group's net profit is expected to record a significant decrease as compared with that of the same period last year.